Mass General Brigham Ventures

The fund holds a proprietary right to review all commercially viable innovations emerging from the Mass General Brigham system, which includes 16 member institutions and over $2 billion in annual NIH-funded research. This provides a structured pipeline unmatched by independent VCs. Deals are sourced through direct relationships with principal investigators, clinician-entrepreneurs, and the technology transfer offices of Harvard Medical School-affiliated hospitals.

Yes, on a selective basis. While the primary pipeline draws from the parent system's research enterprise, the fund has co-invested alongside top-tier healthcare VCs in opportunities originating from other academic medical centers. Its syndication relationships with external venture firms create visibility into non-affiliated deal flow, though the majority of portfolio activity remains tied to the Mass General Brigham innovation ecosystem.

Therapeutics, medical devices, diagnostics, and digital health constitute the core investment verticals, reflecting the clinical strengths of the Mass General Brigham system. Within these verticals, the fund has backed companies in oncology, neurology, cardiology, and infectious disease. The parent system's clinical data assets and patient populations provide validating real-world evidence that underpins many portfolio company value propositions.

Mass General Brigham Ventures operates under a formal conflict-of-interest policy that governs interactions between the investment team, the system's technology transfer offices, and clinician-inventors. Portfolio companies are structured independently, and investment decisions are made by the venture team without interference from the clinical or administrative leadership of the hospitals. This firewall is designed to prevent institutional influence from distorting investment outcomes.